GILTERITINIB
Manner of administration:Oral
Restriction
Indication: Relapsed or refractory Acute Myeloid Leukaemia
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 84 | # of repeats: 0 | DPMQ: $25,145.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Xospata | |||||
Manner of administration:Oral
Restriction
Indication: Relapsed or refractory Acute Myeloid Leukaemia
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 84 | # of repeats: 4 | DPMQ: $25,145.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Xospata | |||||